Eontec Completes Enrollment of All 130 Subjects in Clinical Trial for Degradable Magnesium Interference Screws

Smith+Nephew announced the European commercial launch of its CARTIHEAL AGILI-C Cartilage Repair Implant, initially rolling out across 12 European markets including Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland and the United Kingdom, with additional countries expected to follow. The launch follows the implant's U.S. introduction in 2024 and is part of the company's strategy to expand access to differentiated Sports Medicine technologies. The rollout is backed by a multicenter, randomized controlled trial published in the American Journal of Sports Medicine showing patients treated with CARTIHEAL AGILI-C achieved higher overall Knee injury and Osteoarthritis Outcome Scores than those receiving surgical standard of care through 60 months, with outcomes not statistically different between patients with and without osteoarthritis. The expansion comes as Smith+Nephew's Sports Medicine & ENT revenues rose 10% year over year on a reported basis in the second quarter of 2026, while Sports Medicine Joint Repair revenue rose 11.8%, with the company highlighting strong growth from CARTIHEAL AGILI-C. Smith+Nephew currently has a market capitalization of $11.28 billion, and its shares have lost 18% year to date compared with the industry's 23.4% decline.

Aroa Biosurgery Limited announced positive results from a prospective, multicenter randomized controlled trial of Symphony, published in the International Wound Journal. The study enrolled 143 patients across 10 U.S. sites and found that 55% of diabetic foot ulcers achieved complete wound closure within 12 weeks when Symphony was added to standard of care, compared with 35% receiving standard of care alone, a result with a p-value of 0.039. Mean time to complete wound closure was reduced by 7.8 days, to 65.4 days with Symphony plus standard of care versus 73.2 days with standard of care alone, a result with a p-value of 0.041. The trial enrolled patients with challenging Wagner Grade 1 or 2 diabetic foot ulcers, and patients were randomly assigned to receive weekly Symphony plus standard of care or standard of care alone for up to 12 weeks or until complete wound closure. Lead investigator Dr David Armstrong said the trial demonstrates that combining a novel extracellular matrix bioscaffold with high molecular weight hyaluronic acid can significantly improve wound healing when added to good standard of care. AROA CEO Brian Ward called the results a major milestone for Symphony and said the publication places Symphony among a small group of CAMPs with Level I effectiveness data, strengthening its differentiation and commercial value proposition.

AVITA Medical's updated valuation work now points to a fair value of $12.29, up from the prior $11.06, following the PermeaDerm I data and recent quarterly results. TD Cowen lifted its price target to US$14 from US$12 after a KOL webinar that it said highlighted a clear economic benefit for PermeaDerm compared with allograft with comparable clinical outcomes. BTIG increased its target to US$11 from US$7, citing PermeaDerm I results showing a 70% economic advantage versus allograft based on product cost per % TBSA treated and a 96% reduction in preparation time, and also upgraded AVITA Medical to Buy from Neutral with a US$7 target, pointing to stabilizing reimbursement and U.S. RECELL volume up about 11% sequentially. Lake Street moved its target to US$8 from US$6 after what it called a significant Q2 beat and guide up. The revised fair value reflects a revenue growth assumption of 25.61%, a net profit margin assumption of 17.25%, a future P/E assumption of 19.18x, and a discount rate of 7.72%.